InVivo has an unmatched development portfolio composed of platform technologies for the treatment of both spinal cord injury and other application. These technologies encompass multiple strategies involving biomaterials, U.S. Food & Drug Administration (FDA) approved drugs, growth factors, and human neural stem cells (hNSCs).